Meeting
2020 Gastrointestinal Cancers Symposium
Pancreatic adenosquamous carcinoma: Clinical associations, treatment, and outcomes.
Authors
Mindy L. Hartgers
Mayo Clinic, Rochester, MN
Mindy L. Hartgers , William Bamlet , Rondell P. Graham , Amit Mahipal , Taofic Mounajjed , Sean P. Cleary , Robert R. McWilliams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 751)
Abstract #
751
Poster Bd #
M18
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma.
First Author: Laura Miotke
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti–super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.
First Author: Joon Oh Park
Poster
2022 ASCO Annual Meeting
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.
First Author: Thomas Jens Ettrich